{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:19:52Z","timestamp":1782602392903,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":2807,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1111\/jth.12850","type":"journal-article","created":{"date-parts":[[2015,1,20]],"date-time":"2015-01-20T09:59:49Z","timestamp":1421747989000},"page":"631-642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Anagrelide platelet\u2010lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms"],"prefix":"10.1016","volume":"13","author":[{"given":"Y.R.","family":"Espasandin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Glembotsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Grodzielski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.R.","family":"Lev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.P.","family":"Goette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.C.","family":"Molinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.F.","family":"Marta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.G.","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.12850_bb0010","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJM198805193182002","article-title":"Anagrelide: a new drug for treating thrombocytosis","volume":"318","author":"Silverstein","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12850_bb0015","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9343(92)90017-6","article-title":"Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group","volume":"92","year":"1992","journal-title":"Am J Med"},{"key":"10.1111\/jth.12850_bb0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0049-3848(79)90145-2","article-title":"A potent new inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL\u20104162A)","volume":"15","author":"Fleming","year":"1979","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12850_bb0025","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-0038-1661206","article-title":"Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers","volume":"52","author":"Abe Andes","year":"1984","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12850_bb0030","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.V79.8.1931.1931","article-title":"Analysis of the mechanism of anagrelide\u2010induced thrombocytopenia in humans","volume":"79","author":"Mazur","year":"1992","journal-title":"Blood"},{"key":"10.1111\/jth.12850_bb0035","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1182\/blood.V99.5.1602","article-title":"Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia","volume":"99","author":"Tomer","year":"2002","journal-title":"Blood"},{"key":"10.1111\/jth.12850_bb0040","first-page":"1130","article-title":"Anagrelide\u2010induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies","volume":"88","author":"Thiele","year":"2003","journal-title":"Haematologica"},{"key":"10.1111\/jth.12850_bb0045","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1053\/j.seminhematol.2010.03.005","article-title":"Platelet formation","volume":"47","author":"Thon","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1111\/jth.12850_bb0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.exphem.2005.09.009","article-title":"A preliminary investigation into the action of anagrelide: thrombopoietin\u2010c\u2010Mpl receptor interactions","volume":"34","author":"McCarty","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1111\/jth.12850_bb0055","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1111\/j.1538-7836.2010.03970.x","article-title":"Anagrelide represses GATA\u20101 and FOG\u20101 expression without interfering with thrombopoietinreceptor signal transduction","volume":"8","author":"Ahluwalia","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12850_bb0060","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1016\/0006-2952(88)90054-8","article-title":"Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity","volume":"37","author":"Gillespie","year":"1988","journal-title":"Biochem Pharmacol"},{"key":"10.1111\/jth.12850_bb0065","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood-2007-06-098558","article-title":"PACA and its receptor VPAC1 regulate megakaryocyte maturation: therapeutic implications","volume":"111","author":"Freson","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jth.12850_bb0070","doi-asserted-by":"crossref","first-page":"19207","DOI":"10.1074\/jbc.M112.366476","article-title":"Cyclic AMP signaling inhibits megakaryocytic differentiation by targeting transcription factor 3 (E2A) cyclin\u2010dependent kinase inhibitor 1A (CDKN1A) transcriptional axis","volume":"287","author":"Rubinstein","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.12850_bb0075","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/sj.bjp.0706341","article-title":"Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures","volume":"146","author":"Wang","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1111\/jth.12850_bb0080","series-title":"Investigator\u2032s Brochure: Anagrelide","author":"Schacter","year":"1991"},{"key":"10.1111\/jth.12850_bb0085","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjh.12832","article-title":"Impaired proplatelet formation in immune thrombocytopenia: a novel mechanism contributing to decreased platelet count","volume":"165","author":"Lev","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.12850_bb0090","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.1982.tb03878.x","article-title":"The origin, development and regulation of megakaryocytes","volume":"52","author":"Williams","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.12850_bb0095","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/j.1538-7836.2008.03132.x","article-title":"Adhesive receptors, extracellular proteins and myosin IIA orchestrate proplatelet formation by human megakaryocytes","volume":"6","author":"Balduini","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12850_bb0100","doi-asserted-by":"crossref","first-page":"e21015","DOI":"10.1371\/journal.pone.0021015","article-title":"In vitro megakaryocyte differentiation and proplatelet formation in Ph\u2010negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes","volume":"6","author":"Balduini","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1111\/jth.12850_bb0105","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood-2007-02-071589","article-title":"The May\u2010Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho\u2010ROCK pathway","volume":"110","author":"Chen","year":"2007","journal-title":"Blood"},{"key":"10.1111\/jth.12850_bb0110","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1182\/blood-2006-04-020024","article-title":"Proplatelet formation is regulated by the Rho\/ROCK pathway","volume":"109","author":"Chang","year":"2007","journal-title":"Blood"},{"key":"10.1111\/jth.12850_bb0115","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2013-03-487850","article-title":"CAMP signaling regulates platelet myosin light chain (MLC) phosphorylation and shape change through targeting the RhoA\u2010Rho kinase\u2010MLC phosphatase signaling pathway","volume":"122","author":"Aburima","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.12850_bb0120","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/blood-2003-12-4398","article-title":"Differential regulation of actin stress\/fiber assembly and proplatelet formation by alpha2beta1 integrin and GPVI in human megakaryocytes","volume":"104","author":"Sabri","year":"2004","journal-title":"Blood"},{"key":"10.1111\/jth.12850_bb0125","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/ncomms1704","article-title":"RUNX1\u2010induced silencing of non\u2010muscle myosin heavy chain IIB contributes to megakaryocyte polyploidization","volume":"3","author":"Lordier","year":"2012","journal-title":"Nat Commun"},{"key":"10.1111\/jth.12850_bb0130","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1083\/jcb.201304054","article-title":"The incredible journey: from megakaryocyte development to platelet formation","volume":"201","author":"Machlus","year":"2013","journal-title":"J Cell Biol"},{"key":"10.1111\/jth.12850_bb0135","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.exphem.2012.09.001","article-title":"Differential roles of cAMP and cGMP in megakaryocyte maturation and platelet biogenesis","volume":"41","author":"Begonja","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1111\/jth.12850_bb0140","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0022-3565(25)11019-7","article-title":"Effects of anagrelide on platelet cAMP levels, cAMP\u2010dependent protein kinase and thrombin\u2010induced Ca++ fluxes","volume":"243","author":"Seiler","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/jth.12850_bb0145","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1160\/TH13-08-0681","article-title":"Antithrombotic properties of rafigrelide: a phase 1, open\u2010label, non\u2010randomised, single\u2010sequence, crossover study","volume":"112","author":"Balasubramaniam","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12850_bb0150","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2010-11-318055","article-title":"Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor\u2010induced thrombocytopenia","volume":"117","author":"Bishton","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.12850_bb0155","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/ejh.12342","article-title":"Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes","volume":"93","author":"Murai","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1111\/jth.12850_bb0160","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1172\/JCI75247","article-title":"Proteasome function is required for platelet production","volume":"124","author":"Shi","year":"2014","journal-title":"J Clin Invest"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12850","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12850","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622083921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622083921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.12850\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:10:28Z","timestamp":1761534628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622083921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1538783622083921"],"URL":"https:\/\/doi.org\/10.1111\/jth.12850","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anagrelide platelet\u2010lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.12850","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}